In the LIGHTHOUSE study, Atsena Therapeutics is evaluating ATSN-201 gene therapy for X-linked retinoschisis, leveraging ...

The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) announced opinions for three ...

Researchers at the USC Ginsburg Institute for Biomedical Therapeutics and the USC Roski Eye Institute are advancing a new treatment for dry age-related macular degeneration, a leading cause of ...

The phase 2b/3 clinical trial (NCT05683496) evaluated izokibep versus placebo in non-infectious, non-anterior uveitis.

USC is leading a research team aiming to better understand retinitis pigmentosa and inform future treatments.

HALT, pairs Amarna’s SV40-derived gene delivery vector platform with Phenocell’s in vitro AMD disease model, which accurately ...

Bausch + Lomb announced the acquisition of the ELIOS system, a laser-based technology that offers a new approach to treating ...

Researchers conducted a retrospective study to assess serum inflammatory biomarkers in patients with different subtypes of ...

Nona Biosciences has partnered with Kodiak Sciences to develop multi-target antibodies for ophthalmic diseases. Utilizing ...

SOL-1 is a superiority study being conducted under a Special Protocol Agreement (SPA) with the US Food and Drug ...

EXG102 and EXG202 are investigational gene therapy candidates for wet age-related macular degeneration that are in ...

VisiRose, a company formed in collaboration with Provectus Biopharmaceuticals and the University of Miami Miller School of ...